To investigate a possible candidate for overcoming acquired resistance to ALK‐TKI, we established acquired resistance models to ALK‐TKIs (H3122‐CR and H3122‐LR) by continually exposing EML4‐ALK‐positive H3122 lung cancer cells to increasing doses of crizotinib or ceritinib, after which we performed cell viability screening using a library of FDA‐approved drugs composed of a collection of 640 clinically used compounds. The gene discussed is ALK; the disease is lung cancer.